Why the study?
Are vasomotor symptoms at different stages of menopause associated with increased risk of cardiovascular events and all-cause mortality in postmenopausal women?
Are vasomotor symptoms at different stages of menopause associated with increased risk of cardiovascular events and all-cause mortality in postmenopausal women?
The predictive value of vasomotor symptoms for clinical cardiovascular disease events varies by onset stage, with late-onset symptoms indicating increased CHD and mortality risk, while early symptoms are associated with decreased risk.
May inform individualized CVD risk assessment by VMS timing; observational data leave open causal implications and clinical adoption.
In Brief Objective: Emerging evidence suggests that women with menopausal vasomotor symptoms (VMS) have increased cardiovascular disease (CVD) risk as measured by surrogate markers. We investigated the relationships between VMS and clinical CVD events and all-cause mortality in the Women's Health Initiative Observational Study (WHI-OS). Methods: We compared the risk of incident CVD events and all-cause mortality between four groups of women (total N = 60,027): (1) no VMS at menopause onset and no VMS at WHI-OS enrollment (no VMS [referent group]), (2) VMS at menopause onset but not at WHI-OS enrollment (early VMS), (3) VMS at both menopause onset and WHI-OS enrollment (persistent VMS [early and late]), and (4) VMS at WHI-OS enrollment but not at menopause onset (late VMS). Results: For women with early VMS (n = 24,753), compared with no VMS (n = 18,799), hazard ratios (95% CIs) in fully adjusted models were as follows: major coronary heart disease (CHD), 0.94 (0.84-1.06); stroke, 0.83 (0.72-0.96); total CVD, 0.89 (0.81-0.97); and all-cause mortality, 0.92 (0.85-0.99). For women with persistent VMS (n = 15,084), there was no significant association with clinical events. For women with late VMS (n = 1,391), compared with no VMS, hazard ratios (95% CIs) were as follows: major CHD, 1.32 (1.01-1.71); stroke, 1.14 (0.82-1.59); total CVD, 1.23 (1.00-1.52); and all-cause mortality, 1.29 (1.08-1.54). Conclusions: Early VMS were not associated with increased CVD risk. Rather, early VMS were associated with decreased risk of stroke, total CVD events, and all-cause mortality. Late VMS were associated with increased CHD risk and all-cause mortality. The predictive value of VMS for clinical CVD events may vary with the onset of VMS at different stages of menopause. Further research examining the mechanisms underlying these associations is needed. Future studies will also be necessary to investigate whether VMS that develop for the first time in the later postmenopausal years represent a pathophysiologic process distinct from the classic perimenopausal VMS. In the Women's Health Initiative Observational Study, vasomotor symptoms in perimenopausal women were associated with decreased risks of stroke, total cardiovascular disease events, and all-cause mortality. In contrast, late vasomotor symptoms were associated with increased coronary heart disease risk and all-cause mortality. The predictive value of vasomotor symptoms for clinical cardiovascular disease events may vary with the onset of vasomotor symptoms at different stages of menopause.
No takes yet. Share an insight, caveat, or question.
Szmuilowicz et al. (2011) studied this question.